2 assets in Apocrine Sweat Gland Neoplasm

Therapeutic assets addressing Apocrine Sweat Gland Neoplasm, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Ipilimumab Apocrine Sweat Gland Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)
Nivolumab Apocrine Sweat Gland Neoplasm	National Cancer Institute (NCI)	P2	CCC (53)